1	Strategies for using antigen rapid diagnostic tests to reduce transmission of
2	SARS-CoV-2 in low- and middle-income countries: a mathematical
3	modelling study
4	
5	Alvin X. Han, PhD <sup>1,*</sup> , Sarah Girdwood, MSc <sup>2</sup> , Shaukat Khan, PhD <sup>3</sup> , Jilian A. Sacks, PhD <sup>4</sup> ,
6	Amy Toporowski, MD <sup>4</sup> , Naushin Huq, MA <sup>4</sup> , Emma Hannay, PhD <sup>4</sup> , Colin A. Russell,
7	PhD <sup>1,5,†</sup> , Brooke E. Nichols, PhD <sup>1,4,5,†</sup>
8	
9	<sup>1</sup> Department of Medical Microbiology & Infection Prevention, Amsterdam University
10	Medical Center, University of Amsterdam, Amsterdam, The Netherlands
11	<sup>2</sup> Health Economics and Epidemiology Research Office, Department of Internal Medicine,
12	School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand,
13	Johannesburg, South Africa
14	<sup>3</sup> Clinton Health Access Initiative, Boston, MA, USA
15	<sup>4</sup> Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland
16	<sup>5</sup> Department of Global Health, School of Public Health, Boston University, Boston, MA,
17	USA
18	
19	†Contributed equally
20	*Correspondence to Alvin X. Han (x.han@amsterdamumc.nl)
21	

#### 22 Summary (249/250 words)

#### 23 Background

24 Increasing the availability of antigen rapid diagnostic tests (Ag-RDTs) in low- and middle-

25 income countries (LMICs) is key to alleviating global SARS-CoV-2 testing inequity (median

- testing rate in December 2021-March 2022 when the Omicron variant was spreading in
- 27 multiple countries; high-income countries=600 tests/100,000 people/day; LMICs=14 tests/
- 28 100,000 people/day). However, target testing levels and effectiveness of asymptomatic
- 29 community screening to impact SARS-CoV-2 transmission in LMICs are unclear.

30

## 31 *Methods*

- 32 We used PATAT, an LMIC-focused agent-based model to simulate COVID-19 epidemics,
- 33 varying the amount of Ag-RDTs available for symptomatic testing at healthcare facilities and
- 34 asymptomatic community testing in different social settings. We assumed that testing was a

35 function of access to healthcare facilities and availability of Ag-RDTs. We explicitly

- 36 modelled symptomatic testing demand from non-SARS-CoV-2 infected individuals and
- 37 measured impact based on the number of infections averted due to test-and-isolate.

38

# 39 Findings

40 Testing symptomatic individuals yields greater benefits than any asymptomatic community

- 41 testing strategy until most symptomatic individuals who sought testing have been tested.
- 42 Meeting symptomatic testing demand likely requires ~200-400 tests/100,000 people/day on

43 average as symptomatic testing demand is highly influenced by non-SARS-CoV-2 infected

- 44 individuals. After symptomatic testing demand is satisfied, excess tests to proactively screen
- 45 for asymptomatic infections among household members yields the largest additional
- 46 infections averted.
- 47

### 48 Interpretation

49 Testing strategies aimed at reducing transmission should prioritize symptomatic testing and 50 incentivizing test-positive individuals to adhere to isolation to maximize effectiveness.

- 51
- 52 Funding

53 European Research Council, the Rockefeller Foundation, and the Governments of Germany,

54 Canada, UK, Australia, Norway, Saudi Arabia, Kuwait, Netherlands and Portugal.

#### 55 **Research in context**

### 56 Evidence before this study

57 SARS-CoV-2 transmission can be reduced by test-trace-and-isolate strategies. However,

- 58 large gaps in global COVID-19 testing equity exist: only ~20% of tests administered globally
- so f May 2022 (https://www.finddx.org/covid-19/test-tracker/) were performed in low- and
- 60 middle-income countries (LMICs) where half the world's population reside. To narrow the
- 61 equity gap, expanded access to SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) in
- 62 low-resource settings has been prioritized, with the diagnostics pillar of the global Access to
- 63 COVID-19 Tools (ACT)-Accelerator setting a target testing rate of 100 tests per 100,000
- 64 persons per day (/100k/day). Community testing to detect asymptomatic infected individuals
- has also been proposed to be a key component in bridging the equity gap. We searched
- 66 PubMed and Google Scholar using combinations of search terms (i.e. "SARS-CoV-2",
- 67 "COVID-19", "diagnostic", "testing", "rapid diagnostic tests", "lateral flow tests", "Ag-

68 RDT", "LMIC") and critically reviewed publications and preprints on how scaling up testing

69 availability using Ag-RDTs and implementing community testing programs alongside

- 70 healthcare facility-based symptomatic testing would impact community transmissions in
- 71 LMICs. There is currently no robust quantitative evidence on the strategies or amount of
- testing needed to reduce community transmission of SARS-CoV-2.
- 73

## 74 Added value of this study

- To our knowledge, this is the first study that critically assessed the minimum COVID-19 testing targets set by the ACT-Accelerator in LMICs. This is also the first study that estimated the reduction in secondary SARS-CoV-2 transmissions in LMICs given varying levels of Ag-RDT availability and testing strategies, including the implementation of asymptomatic community testing across different social settings (e.g. households, schools,
- 80 formal workplaces and regular mass gatherings such as religious gatherings). In doing so, this
- 81 is the first robust evidence-base on the utility of using Ag-RDTs to scale-up testing-for-
- 82 mitigation strategies in LMICs.
- 83

#### 84 Implications of all the available evidence

85 Our model showed that testing of symptomatic individuals yields greater reduction in

86 transmissions than any asymptomatic community testing program. Asymptomatic community

87 testing will only support reduced infections after prioritizing available tests for symptomatic

- 88 individuals who sought testing. The current minimum COVID-19 testing rate target of 100
- 89 tests/100k/day can modestly reduce transmissions in LMICs but substantially larger volumes
- 90 of tests are needed to saturate symptomatic testing demand or effectively implement
- 91 community testing.

### 92 Main Text (~3500/3500 words)

### 93 Introduction

94 Since the emergence of SARS-CoV-2 in 2019, the COVID-19 pandemic has resulted in over 500 million confirmed cases and 6 million deaths worldwide as of May 2022.<sup>1</sup> While 95 96 vaccination is the key medical intervention to mitigate the pandemic, SARS-CoV-2 testing 97 remains an important public health tool for case identification and transmission reduction. 98 Testing is especially important in many low- and middle-income countries (LMICs) that 99 continue to struggle with gaining equitable access to global vaccine supplies.<sup>2</sup> Testing is also 100 the backbone of surveillance systems to monitor the emergence of novel variants of concern (VOCs)<sup>3</sup> that may escape immunity acquired from previous infections and vaccination.<sup>4</sup> 101 102 At the same time, the global imbalance in SARS-CoV-2 testing rates is substantial.<sup>5</sup> Between 103 104 December 2021 and March 2022 when the Omicron (BA.1) VOC was spreading in multiple 105 countries, the median testing rate in LMICs was 14 (IQR = 7-41) tests per 100,000 persons 106 per day (/100k/day), whereas HICs tested >43 times more, with a median rate of 603 (IQR = 317-1181) tests/100k/day (https://www.finddx.org/covid-19/test-tracker/). Limited testing has 107 108 likely led to substantial underestimation of COVID-19 prevalence and mortality in LMICs.<sup>6</sup>

109 The diagnostics pillar of the Global Access to COVID-19 Tools (ACT) Accelerator, co-

110 convened by FIND and the Global Fund in partnership with the World Health Organization

111 to enhance access to COVID-19 tests and sequencing, has set a minimum testing rate of 100

112 tests/100k/day.<sup>7</sup> This minimum testing rate is thought to be a "critical threshold to facilitate

113 effective public health interventions".<sup>7</sup> Additionally, asymptomatic testing in a community

setting (i.e. community testing) was identified by this initiative as a crucial step for LMICs to

115 close in on the global equity gap.<sup>7</sup>

116

117 Real-time reverse transcription polymerase chain reaction (PCR) tests remain the gold

118 standard for COVID-19 diagnostic testing, as it is the most sensitive testing method.<sup>8</sup>

119 However, PCR-based testing can be plagued by long turnaround times and necessitate

120 relatively costly laboratory infrastructures, robust sample transport networks and well-trained

- 121 personnel that are lacking in many low-resourced settings.<sup>9</sup> While the sensitivity of antigen
- 122 rapid diagnostic tests (Ag-RDTs) is lower than PCR(>80%)<sup>10</sup>, Ag-RDTs are cheaper, capable
- 123 of producing results in under 30 minutes and can be performed easily at point-of-care.<sup>11</sup> As
- 124 such, Ag-RDTs offer a practical alternative diagnostic tool to enable massive scale up of

testing, including in resource-limited settings, potentially bridging the testing equity gap
 between HICs and LMICs.<sup>5</sup>

127

128 To date, there is no robust evidence-base on how scaling-up Ag-RDTs to 100 tests/100k/day 129 would impact community transmissions. There is also a lack of information on the 130 effectiveness of community testing programs when used to complement symptomatic testing 131 under the constraints of limited test availability. In this study, we developed and used the 132 Propelling Action for Testing and Treating (PATAT) simulation model, an agent-based 133 modelling framework to investigate the impact of using Ag-RDTs for healthcare facility-134 based symptomatic testing. We considered testing programs both with and without additional 135 asymptomatic testing programs in the community, using a population with demographic 136 profiles, contact mixing patterns, and levels of public health resources akin to those in many 137 LMICs. We used PATAT to interrogate how different Ag-RDT distribution availability and 138 testing strategies, including the implementation of community testing in households, schools, 139 formal workplaces and regular mass gatherings such as churches, could impact onward 140 disease transmission. In turn, we aimed to identify key priorities and gaps that should be 141 addressed when implementing mass testing programs using Ag-RDTs in low-resource 142 settings.

143

#### 144 Methods

145 The Propelling Action for Testing And Treating (PATAT) simulation model

146 PATAT first creates an age-structured population of individuals within contact networks of

147 multi-generational households, schools, workplaces, churches (i.e. regular mass gatherings)

- 148 and random community with the given demographic data here based on archetypal LMIC
- 149 estimates (Figure 1). The simulation starts with a user-defined proportion of individuals

150 infected with SARS-CoV-2. Given that viral loads of an infected individual at the time of


- 151 testing affect Ag-RDT sensitivity,<sup>10</sup> PATAT randomly draws a within-host viral load
- 152 trajectory over the course of each individual's infection from known distribution of

153 trajectories<sup>12,13</sup> using previously developed methods.<sup>14</sup> Given conflicting evidence,<sup>15</sup> similar

154 viral load trajectories were drawn for both asymptomatic and symptomatic infected

155 individuals.

156



157

# 158 Figure 1: Schematic of <u>Propelling Action for Testing And Treating (PATAT) simulation model.</u>

159

160 The simulation computes transmission events across different contact networks each day and

161 updates the disease progression of infected individuals based on the SEIRD epidemic model,

stratifying them based on symptom presentation (asymptomatic, mild or severe).

163 Symptomatic individuals may seek symptomatic testing at clinics after symptom onset. Given

that most LMICs are currently testing at rates far below 100 tests/100k/day to the extent that

165 only a small proportion of COVID-19 positive deaths were identified in life (e.g. <10% in

166 Zambia),<sup>16</sup> we assumed that all clinic-provided testing demand by mild symptomatic

167 individuals are satisfied by Ag-RDTs while PCR tests are restricted for testing severe patients

168 only. Positively-tested individuals may go into isolation and their household members may

also be quarantined.

170

## 171 Simulation variables

172 We assumed a populations size of 1,000,000 individuals, creating contact networks and

173 healthcare facilities based on demographic data collected from Zambia.<sup>17</sup> We initialized each

- simulation with 1% of the population being infected by SARS-CoV-2 and ran the model over
- 175 a 90-day period. We permutated a range of values (i.e. 0.9, 1.1, 1.2, 1.5, 2.0, 2.5 and 3.0)
- against varying Ag-RDT stock availability (i.e. 100, 200-1,000 (in 200 increments), 1,000-
- 177 5,000 (in 1,000 increments) tests per 100,000 persons per day). Various test distribution
- 178 strategies were simulated: (1) 85% of weekly allocated tests were used for routine

179 asymptomatic community testing at a social setting and the remaining used for symptomatic 180 testing at healthcare facilities; (2) all weekly allocated test stocks are distributed to healthcare 181 facilities for symptomatic testing only with no asymptomatic community testing and (3) 182 weekly allocated tests are used for symptomatic testing at healthcare facilities first before any 183 remaining tests at the end of the week are used for asymptomatic community testing in the 184 next week. As a baseline, we simulated a set of runs using the same range of  $R_0$  with no 185 testing at all.

186

To determine impact of testing on reducing infections, we assumed that the only public health intervention measure is by test-and-isolate of positive-tested individuals. We also performed a separate set of simulations that require a same-day quarantine of asymptomatic household members of positively-tested individuals. This distinction is important because quarantine should change contact patterns of more individuals per positive test, thereby increasing test utility. We did not consider the quarantine of close contacts outside of household members as contact tracing programs are often resource intensive and discontinued in most countries.

194

### 195 Distribution of routine asymptomatic community test

196 Due to their fixed nature and potential accessibility, routine asymptomatic community testing 197 may be implemented in households, schools, formal workplaces or churches. Community 198 tests stocks may be distributed in each setting in two ways: (1) even distribution to as many 199 entities as possible once per week (e.g. if we have 10 tests available for 10 households per 200 week, then one member of each household would be tested); (2) concentrated distribution to 201 test all individuals in selected entities twice a week who will continue to get tested 202 throughout the epidemic (e.g. if we have 10 tests available for 10 households per week but 203 only one housing 5 members, then all 10 tests will be distributed to this selected household of 204 5 for testing on Monday and Thursday of every week).

205

# 206 Healthcare provided symptomatic testing demand

207 Symptomatic testing demand estimation is particularly challenging for SARS-CoV-2 because


- 208 COVID-19 symptoms overlaps with other respiratory infections, thus increasing testing
- 209 demand. We assumed that symptomatic individuals would seek testing at clinics based on a
- 210 probability distribution that inversely correlate with the distance between their homes and the
- 211 nearest clinic<sup>18</sup> (Table S1). Additionally, we simulated daily demand of clinic tests from

212 individuals that were not infected by SARS-CoV-2 but sought symptomatic testing as they 213 presented with COVID-19-like symptoms. This non-COVID-19 related demand was 214 estimated by assuming a 10% test positivity rate at the start as well as end of an epidemic 215 curve and 20% test positivity rate at the peak, linearly interpolating the demand for periods 216 between these time points (Figure 2). These assumptions are based on observed test positivity 217 rates in multiple countries experiencing infection waves during the second half of 2021.<sup>19</sup> If 218 there are limited clinic test stocks for the day, the available tests are randomly distributed 219 among symptomatic SARS-CoV-2-infected patients and those seeking tests for non-COVID-220 19 related reasons. We assumed that any individual who failed to receive a test due to test 221 shortage would not seek clinic-provided testing again for the rest of their infection. If these 222 individuals had previously decided to self-isolate upon presenting symptoms, they may 223 continue to do so (see Supplementary appendix). Otherwise, we assumed that they would 224 continue to mix with the community.

225

All key parameters are tabulated in Table S1 and full details of PATAT are described in the

- 227 Supplementary appendix. The PATAT model source code is available at
- 228 <u>https://github.com/AMC-LAEB/PATAT-sim.</u>
- 229



230

231 Figure 2: Projected symptomatic testing demand based on assumed case positivity rate. This projected

demand includes both SARS-CoV-2 infected persons who were tested and reported as well as those who seek

233 symptomatic testing for other reasons (e.g. individuals presenting COVID-19-like symptoms but were not


infected with SARS-CoV-2).

235

#### 236 **Results**

- 237 Healthcare provided symptomatic testing demand should be fulfilled first
- 238 We first investigated if routine asymptomatic community testing programs could
- 239 substantially reduce SARS-CoV-2 transmissions in the population. We compared scenarios
- 240 where either all Ag-RDT stocks were used only for symptomatic testing (with no community-
- based testing of asymptomatic populations), or that most tests were used for community
- testing and only 15% of weekly available stocks were allocated for symptomatic testing. The
- 243 proportion of infections averted under each test distribution strategy was computed as a
- 244 measure of impact. Regardless of community testing distribution strategy or , we found
- that setting aside large proportions of Ag-RDTs for community testing led to lower
- 246 proportion of infections averted than if all tests were solely used for symptomatic testing
- 247 (Figure 3). Community testing would only outperform symptomatic testing when the same
- 248 number of available tests saturated symptomatic testing demand in the only-symptomatic
- testing scenario. This conclusion remains the same when household members of all positively
- tested individuals were quarantined (Figure S1).
- 251

252



253

Figure 3: Impact of either using all available Ag-RDT for symptomatic testing or a majority of them


255 (85%) for community testing in various settings (even distribution only; <u>without</u> quarantine of household

256 members). The proportion of secondary infections averted after 90 days relative to the no testing baseline for

- different number of tests available per 100,000 persons per day is plotted for each test distribution strategy. The
   vertical red line denotes the number of tests required to saturate symptomatic testing demand (Figure 4).
- 259

260 Number of tests needed to saturate healthcare provided symptomatic testing demand 261 Given the importance of saturating symptomatic testing demand, we then estimated the 262 number of tests needed to saturate symptomatic testing demand under different (Figure 3 263 and 4A). Besides symptomatic SARS-CoV-2 infected individuals who sought testing, our 264 simulations factored in that 80-90% of symptomatic test stocks were used by individuals who 265 were not infected by SARS-CoV-2 by assuming that test positivity rate ranges at 10%-20% 266 over the course of the infection wave. Under these assumptions, even when 1.2 (where 267 the initial average instantaneous reproduction number ( ) =  $\sim 1.0$ ; Figure 4B), at least 200-268 400 tests/100k/day was needed to ensure all test-seeking individuals were tested. If 1.5269 (initial average 1.6), at least 10 times more tests, in the range of 2,000-5,000 270 tests/100k/day, was needed to satisfy all symptomatic testing demand. These conclusions were similar when household members of positive-tested individuals were quarantined 271 272 (Figure S2).

273





275 Figure 4: Symptomatic testing demand during an epidemic (without quarantine of household members).

(A) Number of symptomatic tests performed per 100,000 persons per day over time for different
 Each
 differently colored shaded curve denotes a different number of tests available per 100,000 persons per day. We

assumed that all healthcare facilities in the community will have new stocks of one week's worth of Ag-RDTs

279 every Monday. The symptomatic testing demand include both symptomatic SARS-CoV-2 infected individuals


who seek testing at healthcare facilities and those who seek symptomatic testing for other reasons based on
assumed case positivity rates (see Methods). The area between the curve plotting the testing rate needed to
saturate symptomatic testing demand ( ) and the curve for testing rate is the amount of symptomatic
testing shortage accumulated over time between those two testing rates. (B) 7-day moving average of
instantaneous reproduction number ( ) over simulated epidemic period (90 days) for different assumed basic
reproduction number ( ).

286

### 287 Marginal impact of symptomatic testing prior to saturating demand

288 We linearly regressed the number of infections averted against test availability to compute 289 the number of additional infections averted with increasing Ag RDT availability, before 290 saturating symptomatic testing demand (Figures 5A-B). Assuming only symptomatic cases 291 that test positive isolate, the largest marginal benefit of increasing Ag-RDT availability for 292 symptomatic testing prior to demand saturation is achieved when  $= 1 \cdot 1 \cdot 1 \cdot 2$ , with close to 293 20,000 additional infections averted for every increase of 100 more Ag-RDTs available for 294 symptomatic testing (Figure 5B; Table 1). When operating at tests availability that meet all 295 symptomatic testing demand, the greatest impact of test-and-isolate is also achieved when 296 =  $1 \cdot 1 - 1 \cdot 2$  with ~40% of total infections averted (Figure 5A).

297



#### 299 Figure 5: Marginal impact of symptomatic testing prior to saturating demand (without quarantine of

**300** household members). (A) Contour plots depicting infections averted relative to the no testing baseline for

301 simulations with different  $R_0$  values and varying number of Ag-RDTs availability. Number of infections averted

302 relative to no testing baseline after 90 days (left panel); Proportion of secondary infections averted relative to no

303 testing baseline after 90 days (right panel). (**B**) Number of additional infections averted for every 100 more Ag-

304 RDTs available prior to saturating symptomatic testing demand for different  $R_0$  values. Dashed red line shows 305 marginal benefit with quarantine of household members while solid black line depicts that without quarantine.

marginal benefit with quarantine of household members while solid black line depicts that without quarantine. (C) Mean daily percentage reduction in transmissions while instantaneous  $R_t$  of simulated epidemic is still > 1

307 for different  $R_0$  values and varying number of Ag-RDTs available for symptomatic testing only. (**D**) Reduction

308 in number of days when instantaneous  $R_t$  of simulated epidemic is > 1 for different  $R_0$  values and varying

309 number of Ag-RDTs available for symptomatic testing only.

310

w/ quarantine of household members	R <sub>0</sub>	No. of additional infections averted per 100 more tests
	0.9	1,772
	1.1	19,807
	1.2	19,372
No	1.5	3,655
	2.0	1,149
	2.5	401
	3.0	216
	0.9	2,205
	1.1	23,444
	1.2	23,250
Yes	1.5	5,702
	2.0	1,999
	2.5	853
	3.0	441

<sup>311</sup> 

312 Table 1: Number of additional infections averted for every 100 more Ag-RDTs available prior to

- 313 saturating symptomatic testing demand for different  $R_0$  values.
- 314

Both the marginal benefit and the maximum infection reduction at demand saturation,

however, diminish exponentially with increasing values of  $R_0$  (Figure 5A-B and Table 1).

317 Nonetheless, there are other impacts that could be gained from performing more symptomatic

testing at values of  $R_0 > 1.2$ . For instance, for  $R_0$  values between 1.5 and 2.0 without

319 quarantining household members, it is possible to reduce daily transmissions by up to 11%


320 with increasing levels of test availability during the growth phase of the epidemic ( $R_t > 1$ ;

321 Figure 5C). Additionally, when  $R_0 \sim 1.5$  and test availability is in the range of 2,000

322 tests/100K/day or more, it is possible to shorten the duration of the epidemic's growth phase

323 (and in turn, the epidemic itself) by about one week (Figure 5D).

- 324
- 325 The marginal benefit of symptomatic testing can be further augmented if asymptomatic
- 326 household members of positively-tested individuals quarantine as well (Figure S3). However,
- 327 depending on and level of test availability, the percentage of infections averted only
- 328 improved modestly by 2-10%. As we assumed that individuals would isolate and quarantine
- 329 in their own homes, infectious individuals in isolation may infect healthy household members
- in quarantine with them.
- 331



332 A symptomatic-testing-first strategy to community testing



No. of tests available per 100,000 persons per day

Figure 6: Symptomatic-testing-first strategy to community testing (without quarantine of household members). When community testing is performed under this strategy, the leftover tests from the previous week's stock allocated for symptomatic testing are used for community testing in various setting in the current week. Two different types of community test distributions approaches (even or concentrated; see Methods) were simulated. The proportion of secondary infections averted after 90 days relative to the no testing baseline for different number of tests available per 100,000 persons per day is plotted for each test distribution strategy. The vertical red line denotes the number of tests required to saturate symptomatic testing demand.

- 341
- 342 Given the importance of symptomatic testing, we then simulated an alternate community
- 343 testing strategy that prioritizes saturating symptomatic testing demand first every week. If
- 344 there were leftover tests from clinics in the previous week, they were used for community
- 345 testing in the following week. We also investigated two ways in which community tests were
- 346 either evenly and randomly distributed in the social setting to as many individuals as possible

or concentrate the available tests to a fixed number of persons throughout the epidemicperiod.

349

350 Even under this symptomatic-testing-first approach, other than households, community

351 testing in almost all social settings only yields greater reduction in infections when test

availability is higher than what is needed to saturate symptomatic testing needs (Figure 6).

353 Overall, household community testing yielded the greatest reduction in transmissions for all

354 simulated values, followed by schools if 1.5. Community testing in churches and


355 formal workplaces only results in modest improvements over symptomatic testing. An even

356 distribution of community tests tends to produce larger reduction in infections. The difference

between even and concentrated community test distributions also increases with larger test

- 358 availability. These results were similarly observed when household members of positively-
- 359 tested individuals were quarantined (Figure S4).
- 360

## 361 Routine community testing in households



363 Figure 7: Routine community testing in households outperforms other settings. (A) Average breakdown of 364 infections based on the social setting where transmissions occurred for the simulations presented in this work. 365 (B) Results from simulations using different testing strategies where  $R_0 = 1.5$ , no quarantine of household 366 members of positively-tested individuals assumed, and Ag-RDT availability of 5,000 tests per 100,000 persons 367 per day. Community testing (even distribution) was performed with a symptomatic-testing-first approach. The 368 average total number of diagnosed cases (left), instantaneous reproduction number ( $R_t$ ; middle) and number of 369 infections averted (right) over the epidemic period are plotted. (C, D) Transmissions across distinct social 370 settings. The top row of stacked plots shows the proportion of infections stratified by the source settings where 371 infectors were infected for each sink setting where their infectees were infected. The stacked bars are colored by 372 the source settings as per the bottom row of bar plots. The bottom row of bar plots shows the contribution of 373 transmission exports into other settings (i.e. transmission events where the infectee were infected in a setting 374 that is different from their infectors) from different source settings where the infectors were infected. (C) No 375 testing baseline results from the example case as in (B). (D) Results from either implementing a symptomatic-376 testing-first community testing in households (left column) or church (right column). The dashed bar outlines 377 are the no testing baseline results as in (C).

378

379 In the symptomatic-testing-first approach, household community testing can achieve greater 380 reduction in transmissions before saturating symptomatic testing demand but only at high 381 levels of test availability (>1,000 tests/100k/day; Figure 6 and S4). There are several reasons 382 why household community testing outperformed other settings. First, large multigenerational 383 homes (mean household size = 5 people) were simulated to mirror what is often found in 384 many LMICs. Second, population in LMICs tend to skew young (i.e. 48% of the population are expected to be  $\leq 15$  years in age).<sup>17</sup> Furthermore, overall employment rates are low (i.e. 385 386 assumed 39% and 23% among men and women respectively)<sup>17</sup> and a large majority of 387 employed individuals likely work in informal employment settings (i.e. assumed 64% and 388 76% among employed men and women respectively)<sup>17</sup> where test distribution is assumed to 389 be difficult or infeasible. Third, dedicated isolation and quarantine facilities are likely rare in 390 low-resource settings. Thus, positively-tested individuals and their close contacts could only 391 isolate/quarantine themselves in their own homes. In turn, almost 60% of all infections 392 observed in a typical simulation arose from transmissions in households. Random community 393 transmissions aside, schools are then the second most common setting where transmissions 394 occurred ( $\sim 14\%$ ) and workplaces, be if formal or informal, the least common (< 3%) (Figure 395 7A).

396

Interestingly, even though we assumed that 70% of all households regularly attended largechurch congregations weekly, churches contributed to a limited proportion of total infections

399 (~5%) (Figure 7A). Yet, if we compare the results between household and church testing at

400 levels of test availability large enough to satisfy symptomatic testing demand (e.g. N =

16

401 5,000), the total number of diagnosed cases over time is actually similar for both community 402 testing strategies (Figure 7B). In fact, testing in churches yielded relatively larger number of 403 cumulative diagnoses by the end of the epidemic but household testing suppressed  $R_t$  more 404 during the growth phase of the epidemic, resulting in greater number of infections averted 405 over time. This is because household testing not only reduces the already higher number of 406 infections taking place in households, it also decreased transmissions between different 407 distinct social settings (e.g. if an infector infected an infectee in the household setting but the 408 infector was infected in school) (Figure 7C-D).

409

# 410 **Discussion**

411 Community asymptomatic testing only achieves high levels of infection reduction after

412 symptomatic testing demand has been saturated. However, the current minimum target of 100

413 tests/100k/day is unlikely to saturate symptomatic testing demand even with scenarios where

414  $R_t < 1$  (i.e. equivalent to simulated epidemics where  $R_0 \le 1.2$ ). Saturating symptomatic

415 testing demand in realistic epidemic wave scenarios where  $R_0 > 1.2$  likely requires >1,000

416 tests/100k/day. This is because testing demand is largely shaped by non-SARS-CoV-2

417 infected individuals due to the overlap of SARS-CoV-2 infection symptoms with other

418 respiratory tract infections. In other words, even before implementing any form of

419 community testing, it is crucial to increase investments in testing capacities that meet

420 symptomatic testing demand first.

421

422 If  $R_0 < 1.5$ , or can be reduced to that point through other public health interventions, 423 increasing testing capacity from 100 tests/100k/day to 200-400 tests/100k/day provides the 424 greatest proportional reduction in secondary transmissions. Furthermore, testing has the 425 potential to be most effective at reducing transmission when  $R_0 < 1.5$ . As SARS-CoV-2 426 outbreaks can have  $R_0$  appreciably above 1.5, it is important to combine testing with other 427 public health measures such as social distancing so as to maximize impact. It is also 428 important to note that the utility of testing in averting infections is predicated on people 429 changing and maintaining their behaviour to reduce contacts following a positive test.<sup>20</sup> 430 Encouraging and incentivizing these changes of behaviour are essential for the effectiveness 431 of any test-and-isolate program, particularly individuals of lower socioeconomic status<sup>21</sup> and 432 communities in low-resource settings.<sup>22</sup> 433


434 As a corroboration of our results, we compared the monthly average testing rate

435 (https://www.finddx.org/covid-19/test-tracker/) to the monthly average values estimated

436 from COVID-19 case counts<sup>23</sup> of 134 countries between December 2021 and March 2022

437 when the Omicron (BA.1) VOC spread rapidly across multiple countries (Figure 8).

- 438 Although the demographic profiles differ between high-income countries (HICs) and LMICs,
- 439 we found that some HICs were expectedly testing at rates that were sufficient or even higher
- 440 than what was likely needed to saturate the symptomatic testing demand we had estimated for
- 441 LMICs at similar epidemic intensity (i.e. values). However, as Omicron (BA.1) cases
- 442 surged, some HICs such as the United States, Germany and Australia were still reportedly
- 443 facing test shortages.<sup>24–26</sup> Based on our results, these countries were indeed falling short of
- 444 meeting symptomatic testing demand (Figure 8). Finally, if we assume that most HICs are
- 445 testing at rates that sufficiently meet symptomatic testing demand, we found that most of
- them were testing at least 200 tests/100k/day, which is in line with our recommendation of
- 447 minimum testing capacity for LMICs.
- 448





450 Figure 8: Global reported COVID-19 testing rate between December 2021 and March 2022 when the

451 **Omicron (BA.1) variant of concern spread rapidly across multiple countries.** Each data point denotes the

452 average monthly reported COVID-19 testing rate of a country against the average instantaneous reproduction

453 number ( ) computed in the same month and is coloured by the income level of the country. Selected data

454 points that are annotated with country names denotes the testing rate on the month at which is the highest

455 during the four-month time period. The shaded area denotes the level of test availability we had estimated to

456 saturate symptomatic testing demand given different equivalent initial values (Figure 4). The red vertical line

457 at 100 tests per 100,000 persons per day is the minimum testing rate target set by the ACT-Accelerator

458 diagnostics pillar. Testing rate data were sourced from the SARS-CoV-2 Test Tracker by FIND

459 (https://www.finddx.org/covid-19/test-tracker/) while  $R_t$  was computed from reported COVID-19 case counts.<sup>23</sup> 460

461 If there are excess tests available after meeting symptomatic testing demand, it is important to 462 critically consider where and how routine community testing of asymptomatic populations is 463 implemented to maximize impact. Given that a larger proportion of infections is expected to 464 occur within households, household community testing after meeting symptomatic testing 465 demand in the previous week would yield greater total infections averted. While testing at 466 regular mass gatherings such as churches every week, for instance, could lead to comparable 467 number of diagnosed infections, doing so only effectively tallies the number of infections that 468 had happened in the week prior and limited infections at these gatherings. Disseminating tests 469 across households, on the other hand, is more effective in not just lowering transmissions 470 occurring in households but likely lessens the number of transmissions between different 471 contact networks as well.

472

There are limitations with our study. First, we assumed that all healthcare facilities will have
access to all Ag-RDT stocks available each week. However, there could be disparities in
stock allocation between different clinics such as prioritizing stock allocation for hospitals.
Such disproportionate distributions could lead to uneven fulfilment of symptomatic testing
demand and consequently affect levels of infections. Nonetheless, our key finding that >100
tests/100k/day is needed to saturate symptomatic testing demand before rolling out
community testing programs is unlikely to change.

480

481 Second, we only modelled scenarios where test-and-isolation was the only public health 482 intervention. Symptomatic testing demand would expectedly be lower if other non-483 pharmaceutical interventions (NPIs) were introduced, and thus potentially improve the utility 484 of community testing at lower test availability. However, the impact of NPIs is confounded 485 by temporal effects<sup>27</sup> and thus difficult to parameterize their mean effects on infection control 486 and in turn, testing demand. Since NPIs effectively decrease the number of secondary 487 transmissions and in turn,  $R_t$ , we expect that the testing demand for a population subjected to 488 NPIs and testing would mirror the demand we had estimated for a population subject to 489 testing only but at lower  $R_t$  values. Analogously, we also did not model how vaccination- and 490 infection-acquired immunity affect testing demand explicitly. However, by the same

491 reasoning that increased population immunity lowers  $R_t$ , the testing demand for a partially

492 immune population should be similar to that of a naïve population at lower  $R_t$  values as well. 493

- 494 Third, we parameterized incubation and virus shedding periods using those empirically
- 495 measured from infections by Wuhan-like SARS-CoV-2<sup>12,28</sup> for this work. However,
- 496 generation intervals have shortened considerably for recent VOCs such as Delta<sup>29</sup> and
- 497 Omicron (BA.1)<sup>30</sup> and could impact the utility of testing in identifying an infection before it
- 498 becomes infectious. However, as demonstrated by the corroboration of our results on
- 499 symptomatic testing demand against empirical testing data collected during the spread of
- 500 Omicron (BA.1) globally, the minimum required test availability of 200 tests/100k/day
- 501 estimated from our results still stand regardless of the circulating variant.
- 502

503 To conclude, Ag-RDTs are a valuable diagnostic tool for COVID-19 testing capacities in

504 LMICs. The target on minimal testing rate of 100 tests/100k/day should be seen as a true

505 minimum if testing is going to be used for reducing transmission but substantially higher

506 testing rates are needed to fulfil likely symptomatic testing demand or effective

- 507 implementation of community testing.
- 508

# 509 **Data sharing**

- 510 All data relevant to the study are included in the Article, the Supplementary Appendix and
- 511 the GitHub repository (<u>https://github.com/AMC-LAEB/PATAT-sim</u>). The PATAT model
- 512 source code can also be found in the GitHub repository
- 513 (<u>https://github.com/AMC-LAEB/PATAT-sim</u>).
- 514

# 515 **Declaration of interests**

- 516 J.A.S., A.T., N.H., E.H. and B.E.N. were employed by FIND, the global alliance for
- 517 diagnostics.
- 518

# 519 Acknowledgements

- 520 A.X.H. and C.A.R. were supported by ERC NaviFlu (No. 818353). C.A.R. was also
- 521 supported by NIH R01 (5R01AI132362-04) and an NWO Vici Award (09150182010027).
- 522 The authors are pleased to acknowledge that all computational work reported in this paper

523	was perfor	rmed c	on the	Shared	Computi	ing Cl	uster v	which :	is adı	ninistere	d by	Bosto	n

- 524 University's Research Computing Services (<u>www.bu.edu/tech/support/research/</u>).
- 525

### 526 Authors' contributions

- 527 A.X.H. contributed to the conceptualization, data curation, formal analysis, investigation,
- 528 methodology, software, validation and visualization of the study. B.E.N. and C.A.R.
- 529 contributed to the conceptualization, data curation, funding acquisition, investigation,
- 530 methodology, project administration, resources, validation and supervision of the study.
- 531 J.A.S., A.T., N.H. and E.H. contributed to the conceptualization, investigation, validation and
- 532 visualization of the study. S.G. and S.K. contributed to the investigation, validation and
- 533 visualization of the study. A.X.H. and C.A.R. wrote the original draft of the manuscript. All
- authors are involved in the review and editing of the manuscript. All authors had full access
- to all data of the study and the final responsibility for the decision to submit for publication.
- 536

# 537 **References**

- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
  real time. *The Lancet Infectious Diseases* 2020; 20: 533–4.
- Ye Y, Zhang Q, Wei X, Cao Z, Yuan H-Y, Zeng DD. Equitable access to COVID-19
  vaccines makes a life-saving difference to all countries. *Nature Human Behaviour*2022 2022; : 1–10.
- 543 3 Viana R, Moyo S, Amoako DG, *et al.* Rapid epidemic expansion of the SARS-CoV-2
  544 Omicron variant in southern Africa. *Nature 2022* 2022; : 1–10.
- 545 4 Straten K van der, Guerra D, Gils MJ van, *et al.* Mapping the antigenic diversification
  546 of SARS-CoV-2. *medRxiv* 2022; : 2022.01.03.21268582.
- 547 5 Batista C, Hotez P, Amor Y ben, *et al.* The silent and dangerous inequity around
  access to COVID-19 testing: A call to action. *eClinicalMedicine* 2022; 43.
- 549 DOI:10.1016/J.ECLINM.2021.101230.
- 550 6 Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. *Nature Reviews*551 *Immunology 2021 21:8* 2021; 21: 469–70.
- 552 7 ACT-Accelerator Strategic Plan & Budget: October 2021 to September 2022.
- 553 https://www.who.int/publications/m/item/act-accelerator-strategic-plan-budget-
- october-2021-to-september-2022 (accessed Feb 19, 2022).

555	8	Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for
556	Ũ	diagnostic COVID-19 tests. <i>Nature Reviews Microbiology</i> 2020 19:3 2020; <b>19</b> : 171–
557		83.
558	9	Mulu A, Bekele A, Abdissa A, et al. The challenges of COVID-19 testing in Africa:
559		the Ethiopian experience. <i>PAMJ 2021; 38:6</i> 2021; <b>38</b> : 1–4.
560	10	Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid
561		diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. <i>PLOS</i>
562		<i>Medicine</i> 2021; <b>18</b> : e1003735
563	11	Onsongo SN, Otieno K, van Duijn S, et al. Performance of a rapid antigen test for
564		SARS-CoV-2 in Kenya. Diagnostic Microbiology and Infectious Disease 2022; 102:
565		115591.
566	12	Linton NM, Kobayashi T, Yang Y, et al. Incubation Period and Other Epidemiological
567		Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A
568		Statistical Analysis of Publicly Available Case Data. Journal of Clinical Medicine
569		2020, Vol 9, Page 538 2020; <b>9</b> : 538.
570	13	Kissler SM, Fauver JR, Mack C, et al. Viral dynamics of acute SARS-CoV-2 infection
571		and applications to diagnostic and public health strategies. PLOS Biology 2021; 19:
572		e3001333
573	14	Quilty BJ, Clifford S, Hellewell J, et al. Quarantine and testing strategies in contact
574		tracing for SARS-CoV-2: a modelling study. The Lancet Public Health 2021; 6: e175-
575		83.
576	15	Boyton RJ, Altmann DM. The immunology of asymptomatic SARS-CoV-2 infection:
577		what are the key questions? Nature Reviews Immunology 2021 21:12 2021; 21: 762-8.
578	16	Gill CJ, Mwananyanda L, MacLeod W, et al. Sustained high prevalence of COVID-19
579		deaths from a systematic post-mortem study in Lusaka, Zambia: one year later.
580		medRxiv 2022; : 2022.03.08.22272087.
581	17	Zambia Statistics Agency. 2019 Labour Force Survey Report. 2019.
582		https://www.zamstats.gov.zm/index.php/publications/category/7-labour (accessed Jan
583		26, 2022).
584	18	Dovel K, Balakasi K, Gupta S, et al. Frequency of visits to health facilities and HIV
585		services offered to men, Malawi. Bull World Health Organ 2021; 99: 618-26.
586	19	Hasell J, Mathieu E, Beltekian D, et al. A cross-country database of COVID-19
587		testing. Scientific Data 2020 7:1 2020; 7: 1–7.

588	20	Pavelka M, Van-Zandvoort K, Abbott S, et al. The impact of population-wide rapid
589		antigen testing on SARS-CoV-2 prevalence in Slovakia. <i>Science (1979)</i> 2021; <b>372</b> :
590		635–41.
591	21	Sweeney S, Capeding TPJ, Eggo R, et al. Exploring equity in health and poverty
592		impacts of control measures for SARS-CoV-2 in six countries. <i>BMJ Global Health</i>
593		2021; <b>6</b> : e005521.
594	22	Torres-Rueda S, Sweeney S, Bozzani F, et al. Stark choices: exploring health sector
595		costs of policy responses to COVID-19 in low-income and middle-income countries.
596		<i>BMJ Global Health</i> 2021; <b>6</b> : e005759.
597	23	Abbott S, Hickson J, Badr HS, et al. epiforecasts/EpiNow2: Beta release. 2021;
598		published online June 28. DOI:10.5281/ZENODO.5036949.
599	24	Reuters. U.S. testing struggles to keep up with Omicron. 2021; published online Dec
600		22. https://www.reuters.com/world/us/us-testing-struggles-keep-up-with-omicron-
601		2021-12-22/ (accessed April 7, 2022).
602	25	DW News. Germany faces PCR test bottlenecks. 2022; published online Jan 14.
603		https://www.dw.com/en/germany-faces-pcr-test-bottlenecks/av-60431333 (accessed
604		April 7, 2022).
605	26	BBC News. Covid: Australians desperate for tests amid Omicron surge. 2022;
606		published online Jan 4. https://www.bbc.com/news/world-australia-59864428
607		(accessed April 7, 2022).
608	27	Sharma M, Mindermann S, Rogers-Smith C, et al. Understanding the effectiveness of
609		government interventions against the resurgence of COVID-19 in Europe. Nature
610		Communications 2021 12:1 2021; 12: 1–13.
611	28	Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized
612		patients with COVID-2019. Nature 2020 581:7809 2020; 581: 465-9.
613	29	Kang M, Xin H, Yuan J, et al. Transmission dynamics and epidemiological
614		characteristics of Delta variant infections in China. medRxiv 2021; :
615		2021.08.12.21261991.
616	30	Hay JA, Kissler SM, Fauver JR, et al. Viral dynamics and duration of PCR positivity
617		of the SARS-CoV-2 Omicron variant. medRxiv 2022; : 2022.01.13.22269257.
618		